A forum for researchers, students and applicants in the field of cyclodextrin technology
Dec 9, 2021 – Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through
Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and
Pfizer’s breakthrough drug candidate PF-07321332 used in combination with ritonavir was poven to successfully reduce the risk of hospitalization and
Jubilant Pharmova subsidiary Jubilant Pharma has concluded safety and pharmacokinetic/absorption studies of a new oral formulation of remdesivir in animals
As repurposing ivermectin against Covid-19 is still in the focus of debates and as this drug can be formulated with
Aequus Pharmaceuticals Inc. and reVision Therapeutics, Inc. (“reVision”) announced a collaboration on the development of a therapy for Stargardt disease.
Mallinckrodt Pharmaceuticals has reached an agreement to divest and transfer the Investigational New Drug (IND) application for experimental drug adrabetadex
CBT-006 is a molecule developed by Cloudbreak Therapeutics that can sequester cholesterol. CBT-006 is a unique topical formulation following 505b(2)
New leading international life science investors join current institutional investors with proceeds to: Advance novel, late-stage Investigational ophthalmology drugs OCS-01
